10-K: FibroGen's 2023 Annual Report: Focus on Pancreatic Cancer Trials and Roxadustat Growth

FibroGen's 2023 annual report highlights progress in pancreatic cancer trials, roxadustat sales growth in China, and strategic pipeline advancements.

Summary

• FibroGen's 2023 saw significant progress with multiple Phase 3 trial results, advancement of pancreatic cancer trials for pamrevlumab, and preclinical work on new product candidates.
• The company in-licensed a new product candidate, FG-3246, and continued to experience robust sales growth of roxadustat in China for anemia associated with chronic kidney disease (CKD).
• In 2024, FibroGen anticipates an approval decision in China for roxadustat in chemotherapy-induced anemia (CIA) and will present data from two pivotal pancreatic cancer trials of pamrevlumab.
• Roxadustat has captured approximately 42% value share within the segment of erythropoiesis-stimulating agents (ESAs) and HIF-PH inhibitors in China as of December 2023.
• The company expects continued growth of roxadustat sales in China due to continued adoption by patients and doctors and the recent two-year renewal on the 2023 National Reimbursement Drug List with a limited price reduction of 7%.
• Approximately 64,000 people were diagnosed with pancreatic cancer in the U.S. in 2023, and approximately 50,000 people died of pancreatic cancer.
• The company completed enrollment of 284 patients in the LAPIS trial for locally advanced pancreatic cancer (LAPC) and expects topline data in mid-2024.
• The pamrevlumab portion of the Precision Promise trial for metastatic pancreatic cancer was completed in the first quarter of 2024, with topline results expected in the second quarter of 2024.
• The company had a total of 486 employees as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in roxadustat sales in China and advancements in the pipeline, the termination of the AstraZeneca collaboration and the failure of pamrevlumab trials in IPF and DMD are significant setbacks. The company also faces financial challenges and competition, leading to a neutral sentiment.

Positives

• Roxadustat sales in China continue to see significant volume growth.
• The company has a strong pipeline of novel therapeutics.
• The company has a new partnership with Fortis Therapeutics to develop FG-3246.
• The company has a high employee engagement score of 89% overall.
• The company has been able to contain regrettable turnover to less than 6%, and closed 2023 with only 3.1% regrettable losses.

Negatives

• The company is substantially dependent on the success of pamrevlumab and roxadustat.
• The company faces substantial competition in the discovery, development and commercialization of product candidates.
• The company has incurred significant losses since its inception and anticipates that it will continue to incur losses for the foreseeable future.
• The company terminated its collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in the U.S. and all territories except for China and those territories previously licensed to Astellas.
• The company faces competition from generics that could enter the market after expiry of its composition of matter patent for roxadustat.
• The company's Phase 3 trials of pamrevlumab in IPF and DMD did not meet their primary endpoints.

Risks

• The company may be unable to obtain regulatory approval for its product candidates.
• Clinical trial results may not be indicative of results in larger trials.
• Product candidates may cause undesirable side effects.
• The company relies on third parties for manufacturing and distribution.
• The company may have shortfalls, delays, or excesses in manufacturing.
• The company's intellectual property may not be adequately protected.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
• The company's operations in China are subject to significant risks.
• The company may experience difficulties in successfully growing and sustaining sales of roxadustat in China.
• The company's retail prices of any product candidates will be subject to pricing control in China and elsewhere.
• The company may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to its operations in China.
• The company may be subject to tax inefficiencies associated with its offshore corporate structure.
• The company may be subject to legal proceedings and intellectual property disputes.

Future Outlook

FibroGen expects continued growth of roxadustat sales in China and anticipates an approval decision in China for roxadustat in CIA in mid-2024. The company also expects to report topline results from its two ongoing pivotal studies of pamrevlumab in 2024.

Management Comments

• In 2024, we will focus on expanding the population treated with roxadustat, as well as the duration of treatment, which we believe is important in effective management of anemia in CKD.
• We believe roxadustat has become the standard of care for the treatment of anemia in CKD in China.

Industry Context

The pharmaceutical and biotechnology industries are highly competitive, particularly in areas like pancreatic cancer and anemia in CKD. FibroGen faces competition from multiple other companies, many with greater resources. The company also faces competition from generics that could enter the market after expiry of its composition of matter patent for roxadustat.

Comparison to Industry Standards

• The report mentions that the major market sales of pancreatic cancer drugs are estimated to grow from $1.3 billion in 2016 to approximately $3.7 billion in 2026, indicating a significant market opportunity.
• The report notes that the 5-year survival rate for pancreatic cancer is only 12%, highlighting the unmet medical need and potential for new therapies like pamrevlumab.
• The report states that roxadustat has captured approximately 42% value share within the segment of erythropoiesis-stimulating agents (ESAs) and HIF-PH inhibitors in China, indicating a strong market position compared to other treatments.
• The report mentions that EVRENZO is one of five HIF-PH inhibitors currently on the market in Japan, indicating a competitive landscape in that region.

Legal Proceedings

• The company and certain of its current and former executive officers have been named as defendants in a consolidated putative class action lawsuit.
• Certain of the company's current and former executive officers and directors have been named as defendants in several derivative lawsuits.
• The company received a subpoena from the SEC requesting documents related to roxadustats pooled cardiovascular safety data.

Related Party Transactions

• The company has significant related party transactions with Astellas and Falikang.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the success of its product candidates.
• Employees may be impacted by the company's restructuring efforts and changes in compensation.
• Patients may benefit from the development of new therapies for pancreatic cancer and anemia.
• The company's collaboration partners may be impacted by the success of its product candidates and the terms of its agreements.

Next Steps

• The company expects an approval decision in China for roxadustat in CIA in mid-2024.
• The company will present data from two pivotal pancreatic cancer trials of pamrevlumab in 2024.
• The company anticipates the initiation of a PET biomarker-driven Phase 2 trial of FG-3246 for mCRPC in the second half of 2024.
• The company plans to submit an investigational new drug application (IND) for FG-3165 in the first quarter of 2024 and for FG-3175 in 2025.

Key Dates

Keywords

roxadustat, pamrevlumab, pancreatic cancer, anemia, chronic kidney disease, chemotherapy-induced anemia, myelodysplastic syndromes, prostate cancer, FG-3246, FG-3165, FG-3175, China, clinical trials, regulatory approval, biotechnology, pharmaceuticals